Using small molecules (purine analogs) scientists managed to reverse multidrug resistance in lung cancer, a common obstacle to successful cancer chemotherapy.
BELGRADE, Serbia, Oct. 14 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch
See direct link http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=24984
The company is using this opportunity to shed some light the significance of that filing. The MindUp group focused their investigation on inactivation of tumour suppressors as molecular marker events highly related to the pathogenesis of non-small cell lung carcinoma (NSCLC). To that end, they use paired tumour and normal lung tissue samples and blood obtained from patients with NSCLC after surgery. These results are presented at AACR (American Association for Cancer Research) Conference, Frontiers in Basic Cancer Research, http://www.aacr.org/home/scientists/meetings--workshops/frontiers-in-cancer-prevention-research.aspx October 8 - 11, 2009. Boston, Massachusetts, on poster entitled "The impact of inactivation of p53 and PTEN tumor suppressors on promotion and progression of human non-small cell lung carcinoma" (authors: Tijana Andjelkovic, Jasna Bankovic, Vedrana Milinkovic, Ana Podolski, Sabera Rudijic, Nikola Tanic).
For example a recent article (see Globe and Mail Newspaper unauthorized link: http://www.theglobeandmail.com/news/national/canadians-uncover-the-cancer-map/article1316312/ ) reports that a team of British Columbia based scientists decodes the metastatic breast-cancer genome, shedding light on how tumours develop by understanding their mutations. The landmark achievement opens up a world of new ways to fight the disease - including personalized treatments.
MindUp cancer project scientists are of the opinion that their work is further advanced then the aforementioned, because their research led to the identification of genes associated with lung cancer promotion and progression, that may be potential biomarkers and useful for personalized therapy. Using small molecules (purine analogs) they managed to reverse multidrug resistance in lung cancer, a common obstacle to successful cancer chemotherapy.
As per the news release of yesterday Oct 13 2009 and a Filing of October 1 2009 Titled "Shareholders FAQ on Mellow Hope Slavica and HTDS" http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=24872 the company will be meeting early next week with the principal representatives of the Canadian Pharmaceutical company in Belgrade Serbia in regards to the Slavica Bio Chem's MindUp cancer project and its planned split off. The company sees this as a significant event for its MindUp cancer project, and brings attention to that filing.
Progress on the MindUp will be reported back at earliest by next week.
To receive regular updates on HTDS please sign up or opt in with your email address at this link http://www.minamargroup.com/updates/
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact firstname.lastname@example.org; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR), 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A), Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)
SOURCE Hard to Treat Diseases
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All